Finding an effective method of preventing the possibility of stroke is something that medical science has grappled with for decades. Now, Algernon Pharmaceuticals, a clinical stage biopharmaceutical development company, looks to be making significant headway by repurposing a known psychedelic compound that is part of the tryptamine family to help battle stroke.

The Stockhouse interview with Algernon CEO Christopher J. Moreau has been broken down into four separate segments for your convenience

Part 1
CEO Christopher J. Moreau begins the interview with a short introduction to the Company and provides an explanation for DMT as a clinical drug.


Part 2
CEO Christopher J. Moreau explains the decision as to why DMT and why has Algernon Pharmaceuticals chosen Hammersmith Medicines Research in the UK to run the upcoming clinical trials.


Part 3
CEO Christopher J. Moreau explains the government approval process and other clinical trials such as Ifenprodil, and other potential trials to come including pancreatic cancer.


Part 4
CEO Christopher J. Moreau discusses the Algernon Pharmaceuticals management team, the current valuations and the key milestones for the year.

Algernon Pharmaceuticals Inc. (CSE.AGN, OTCQB:AGNPF, FRANKFURT: AGW, Forum) is a biopharmaceutical company that investigates safe, already approved drugs – including naturally occurring compounds – for new disease applications, moving them efficiently and safely into new human trials. This enables the company to develop new formulations while seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.